{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:45:17Z","timestamp":1790203517524,"version":"4.1.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[1996,4,1]],"date-time":"1996-04-01T00:00:00Z","timestamp":828316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,9]],"date-time":"2020-01-09T00:00:00Z","timestamp":1578528000000},"content-version":"vor","delay-in-days":8683,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[1996,4]]},"DOI":"10.1093\/oxfordjournals.annonc.a010604","type":"journal-article","created":{"date-parts":[[2012,4,18]],"date-time":"2012-04-18T21:42:58Z","timestamp":1334785378000},"page":"373-379","source":"Crossref","is-referenced-by-count":45,"title":["Long-term survival following cladribine (2-chlorodeoxyadenosine) therapy in previously treated patients with chronic lymphocytic leukemia"],"prefix":"10.1016","volume":"7","author":[{"given":"G.","family":"Juliusson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Liliemark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0005","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1093\/oxfordjournals.annonc.a059151","article-title":"Chronic lymphocytic leukemia; Present status","volume":"6","author":"Montserrat","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0010","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1093\/oxfordjournals.annonc.a059209","article-title":"Purine analogs in the treatment of low-grade lymphomas and chronic lymphocytic leukemias","volume":"6","author":"Pott-Hoeck","year":"1995","journal-title":"Ann Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0015","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1021\/ja01487a055","article-title":"Synthesis of potential anti-cancer agents. XX. 2-fluoropurines","volume":"82","author":"Montgomery","year":"1960","journal-title":"J Am Chem Soc"},{"issue":"Suppl 8","key":"10.1093\/oxfordjournals.annonc.a010604_bb0020","first-page":"49","article-title":"Fludarabine phosphate in the treatment of chronic lymphocytic leukemia","volume":"17","author":"Keating","year":"1990","journal-title":"Semin Oncol"},{"issue":"Suppl I","key":"10.1093\/oxfordjournals.annonc.a010604_bb0025","first-page":"169","article-title":"A randomised comparison between fludarabine and cyclophosphamide, adriamycin and prednisolone in the treatment of chronic lymphocytic leukaemia","volume":"87","author":"Johnson","year":"1994","journal-title":"Br J Haematol"},{"issue":"Suppl 1","key":"10.1093\/oxfordjournals.annonc.a010604_bb0030","first-page":"607a","article-title":"for CALGB, SWOG, CTG\/ NCIC, ECOG and NCI. Fludarabine induces a high complete remission rate in previously untreated patients with active chronic lymphocytic leukemia. A randomized inter-group study","volume":"86","author":"Rai","year":"1995","journal-title":"Blood"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0035","first-page":"337","article-title":"Long-term follow-up of patients with chronic lymphocytic leukemia receiving fludarabine regimens as initial therapy","volume":"14","author":"Keating","year":"1995","journal-title":"Proc Am Soc Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0040","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/0140-6736(92)92826-2","article-title":"Cladribine (2-chlorodeoxyadenosine)","volume":"340","author":"Beutler","year":"1992","journal-title":"Lancet"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0045","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJM199004193221605","article-title":"Lasting remission in hairy-cell leukemia induced by a single infusion of 2-chloro-deoxyadenosine","volume":"322","author":"Piro","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0050","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1200\/JCO.1992.10.3.371","article-title":"2-Chlorodeoxyadenosine treatment of low-grade lymphomas","volume":"10","author":"Kay","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0055","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1182\/blood.V84.3.733.733","article-title":"2-Chlorodeoxyadenosine therapy in patients with T-cell lymphoproliferative disorders","volume":"84","author":"O'Brien","year":"1994","journal-title":"Blood"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0060","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1200\/JCO.1994.12.12.2694","article-title":"Primary therapy of Waldenstrom's macroglobulinemia with 2-chlorodeoxy-adenosine","volume":"12","author":"Dimopoulos","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0065","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1182\/blood.V84.4.1237.1237","article-title":"Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia","volume":"84","author":"Santana","year":"1994","journal-title":"Blood"},{"issue":"Suppl 1","key":"10.1093\/oxfordjournals.annonc.a010604_bb0070","first-page":"12","article-title":"2-Chlorodeoxyadenosine (CdA) with and without cytosin arabinoside (ara-C) and idarubicin for acute myeloid and lymphoid leukemia - clinical and pharmacokinetic studies","volume":"87","author":"Juliusson","year":"1994","journal-title":"Br J Haematol"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0075","doi-asserted-by":"crossref","first-page":"430","DOI":"10.7326\/0003-4819-121-6-199409150-00006","article-title":"2-Chlorodeoxyadenosine-in-duced complete remission in Langerhans-cell histiocytosis","volume":"121","author":"Saven","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0080","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(94)91046-4","article-title":"Cladribine in treatment of chronic progressive multiple sclerosis","volume":"344","author":"Sipe","year":"1994","journal-title":"Lancet"},{"issue":"Suppl 1","key":"10.1093\/oxfordjournals.annonc.a010604_bb0085","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3109\/10428199109103394","article-title":"2-Chlorodeoxyadenosine treatment of refractory chronic lymphocytic leukemia","volume":"5","author":"Saven","year":"1991","journal-title":"Leuk Lymphoma"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0090","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1200\/JCO.1995.13.3.570","article-title":"2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia","volume":"13","author":"Saven","year":"1995","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0095","first-page":"1130","article-title":"2-Chlorodeoxyadenosine (CdA) for patients with previously untreated chronic lymphocytic leukemia (CLL)","volume":"9","author":"Delannoy","year":"1995","journal-title":"Leukemia"},{"issue":"Suppl 1","key":"10.1093\/oxfordjournals.annonc.a010604_bb0100","first-page":"349a","article-title":"for the Australian Leukemia Study Group. 2-Chlorodeoxyadenosine in previously untreated chronic lymphocytic leukemia - preliminary analysis from the Australian Leukemia Study Group trial","volume":"86","author":"Mulligan","year":"1995","journal-title":"Blood"},{"issue":"Suppl","key":"10.1093\/oxfordjournals.annonc.a010604_bb0105","first-page":"141a","article-title":"Oral 2-chlorodeoxyadenosine as primary treatment for symptomatic chronic lymphocytic leukemia","volume":"82","author":"Juliusson","year":"1993","journal-title":"Blood"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0110","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.1996.14.7.2160","article-title":"Oral cladribine as primary therapy for patients with B-cell chronic lymphocytic leukemia","volume":"14","author":"Juliusson","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0115","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1200\/JCO.1993.11.4.679","article-title":"High complete remission rate from 2-chloro-2\u2032-deoxyadenosine (CdA) in previously treated patients with B-cell chronic lymphocytic leukemia: Response predicted by rapid decrease of blood lymphocyte count","volume":"11","author":"Juliusson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0120","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/ajh.2830290307","article-title":"Guidelines for clinical protocols for chronic lymphocytic leukemia: Recommendations of the National Cancer Institute-sponsored Working Group","volume":"29","author":"Cheson","year":"1988","journal-title":"Am J Hematol"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0125","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1002\/1097-0142(19810701)48:1<198::AID-CNCR2820480131>3.0.CO;2-V","article-title":"A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis","volume":"48","author":"Binet","year":"1981","journal-title":"Cancer"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0130","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1056\/NEJM199210083271504","article-title":"Response to 2-chlorodeoxyadenosine in patients with B-cell chronic lymphocytic leukemia resistant to fludarabine","volume":"327","author":"Juliusson","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0135","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3109\/10428199409051654","article-title":"Retreatment of B-cell chronic lymphocytic leukemia with 2-chlorodeoxyadenosine (CdA) at relapse following CdA-induced remission. No acquired resistance","volume":"13","author":"Juliusson","year":"1994","journal-title":"Leuk Lymph"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0140","series-title":"Lancet","article-title":"Fludarabine versus cyclophosphamide, doxorubicin, prednisone (CAP) for the treatment of advanced stage chronic lymphocytic leukemia. Results of a multicenter prospective randomized study","author":"The French Cooperative Group on CLL","year":"1996"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0145","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1182\/blood.V82.4.1366.1366","article-title":"Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia","volume":"82","author":"Rabinowe","year":"1993","journal-title":"Blood"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0150","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1200\/JCO.1994.12.4.748","article-title":"Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: Preliminary results","volume":"12","author":"Khouri","year":"1994","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0155","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/oxfordjournals.annonc.a058693","article-title":"High incidence of infections after 2-chlorodeoxyadenosine (2-CDA) therapy in patients with malignant lymphomas and chronic and acute leukaemias","volume":"5","author":"Betticher","year":"1994","journal-title":"Ann Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0160","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJM199402033300504","article-title":"Lack of effect of 379 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy","volume":"330","author":"O'Brien","year":"1994","journal-title":"N Engl J Med"},{"issue":"Suppl 6","key":"10.1093\/oxfordjournals.annonc.a010604_bb0165","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2165\/00003495-199400476-00005","article-title":"Immunologic and genetic abnormalities in chronic lymphocytic leukaemia","volume":"47","author":"Juliusson","year":"1994","journal-title":"Drugs"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0170","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1182\/blood.V83.12.3672.3672","article-title":"Flow cytometry of blood and bone marrow cells in hairy cell leukemia. Phenotype of hairy cells and lymphocyte subsets following treatment with 2-chlorodeoxyadenosine","volume":"83","author":"Juliusson","year":"1994","journal-title":"Blood"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0175","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1200\/JCO.1992.10.10.1514","article-title":"On the bio-availability of oral and subcutaneous 2-chloro-2\u2032-deoxyadenosine in humans: Alternative routes of administration","volume":"10","author":"Liliemark","year":"1992","journal-title":"J Clin Oncol"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0180","first-page":"385","article-title":"Cellular pharmacokinetics of 2-chloro-2\u2032-deoxyadenosine nucleotides: Comparison of intermittent and continuous intravenous infusion and subcutaneous and oral administration in leukemia patients","volume":"1","author":"Liliemark","year":"1995","journal-title":"Clin Cancer Res"},{"key":"10.1093\/oxfordjournals.annonc.a010604_bb0185","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1200\/JCO.1995.13.4.989","article-title":"Subcutaneous injection of 2-chlorodeoxyadenosine for symptomatic hairy cell leukemia","volume":"13","author":"Juliusson","year":"1995","journal-title":"J Clin Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419605879?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419605879?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/7\/4\/373\/475603\/7-4-373.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,21]],"date-time":"2020-02-21T01:04:21Z","timestamp":1582247061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419605879"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,4]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1996,4]]}},"alternative-id":["S0923753419605879"],"URL":"https:\/\/doi.org\/10.1093\/oxfordjournals.annonc.a010604","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[1996,4]]}}}